Teva cleared to market generic cancer drugs from Nov. 2013

18.07.2011                      16.Tammus, 5771

Medizin:

Teva cleared to market generic cancer drugs from Nov. 2013

Neopogen expedites the creation of white blood cells in people undergoing chemotherapy. The cancer therapy hits cells in a state of rapid multiplication, which includes the cancer cells – and white blood cells, leukocytes, which exposes the patient to infection.

Teva Pharmaceutical Industries took a major step toward launching its first big line of bio-generic products in the U.S. after signing an agreement with Amgen that settles patent claims on two products. The two drugs, Neulasta and Neopogen, have combined U.S. sales of $3.7 billion in the last 12 months.
Neopogen expedites the creation of white blood cells in people undergoing chemotherapy. The cancer therapy hits cells in a state of rapid multiplication, which includes the cancer cells – and white blood cells, leukocytes, which exposes the patient to infection….